Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

• Van Den Bent, Martin J. Erasmus MC Cancer Center, Rotterdam, Netherlands;
• French, Pim Erasmus MC, Rotterdam, Netherlands;
• Eoli, Marica Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy;
• Sepúlveda, Juan M. Hospital Universitario 12 de Octubre, Madrid, Spain;
• Walenkamp, Anna Maria Elisabeth Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands;
• Frenel, Jean-Sebastien Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France;
• Franceschi, Enrico Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy;
• Clement, Paul M. Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium;
• Weller, Michael Laboratory of Molecular Neuro-Oncology, Department of Neurology, and Neuroscience Center Zurich, University Hospital and University of Zurich, Zurich, Switzerland;
• de Heer, Iris Erasmus MC, Rotterdam, Netherlands;
• Looman, Jim Abbvie, Chivcago, IL;
• Dey, Jyotirmoy AbbVie, Cicago, IL;
• Krause, Scott AbbVie, Chicago, IL;
• Xiong, Hao AbbVie Inc., Chicago, IL;
• Ansell, Peter J AbbVie Inc., North Chicago, IL;
• Nuyens, Sarah EORTC Headquarters, Brussels, Belgium;
• Spruyt, Maarten EORTC Headquarters, Brussels, Belgium;
• Brilhante, Joana EORTC Headquarters, Brussels, Belgium;
• Gorlia, Thierry EORTC Headquarters, Brussels, Belgium;
• Golfinopoulos, Vassilis EORTC Headquarters, Brussels, Belgium;

Cancer Research

Oncology